3 mg [14C]-A4250 capsule ( DrugBank: - )

---

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
93	原発性胆汁性胆管炎	1
297	アラジール症候群	1
338	進行性家族性肝内胆汁うっ滞症	1

93. 原発性胆汁性胆管炎

---

臨床試験数 : 298 /  薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom

297. アラジール症候群

---

臨床試験数 : 45 /  薬物数 : 21 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom

338. 進行性家族性肝内胆汁うっ滞症

---

臨床試験数 : 60 /  薬物数 : 26 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom